Hirschsprung Disease Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Hirschsprung Disease Treatment Market Overview

Hirschsprung Disease Treatment Market is estimated to reach at a high CAGR during the forecast period (2024-2031).

Hirschsprung disease is a condition in which nerves in certain gut regions are missing. When the nerves in the colon (enteric nerves) do not grow properly before birth, this disorder develops (embryonic development). Although less severe cases are found later in infancy, this illness is usually detected in the first two months of life. Treatment consists of surgery required to bypass the affected part of the colon or remove it entirely, and medications are also preferred in fewer severe cases.

Market Scope

To Know More Insights - Download Sample

Market Dynamics

Innovative research in the Hirschsprung disease treatment is expected to drive market growth.

Hirschsprung disease is a condition that is both complex and heterogeneous. There has been increasing innovative research for hirschsprung disease treatment in children. For instance, In stem cell research, neuronal stem cells are being used to repopulate the aganglionic intestine in children with Hirschsprung disease. This groundbreaking study reveals a promising new therapeutic option for children with Hirschsprung disease, especially those with more severe forms of aganglionosis. Moreover, pediatricians and primary care physicians will have all of the knowledge and resources to successfully manage and treat children with Hirschsprung disease by continuing research, education, and the application of the most current technologies in diagnostic and treatment approaches. Thus, the market is expected to drive in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 has many consequences, including a shortage of subcontractors and materials, supply chain interruptions, and contract terminations to save costs. Moreover, the COVID-19 epidemic has significantly impacted pediatric surgery practices, including elective and outpatient procedures. The pandemic had a significant impact on the quantity and sorts of patients operated on. Strict adherence to the procedure caused an increase in the cost of definitive management by delaying emergency therapy. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Market Segment Analysis

Surgery segment is expected to hold the largest market share in hirschsprung disease treatment market

The surgery segment is expected to dominate in 2021. The segment benefits because hirschsprung's illness is usually treated with surgery to bypass or eliminate the colon section devoid of nerve cells. This is accomplished in one of two ways either a pull-through operation or an ostomy procedure. For instance, Pull-through surgery is the procedure lining of the diseased part of the colon is stripped away. Then, the normal section is pulled through the colon from the inside and attached to the anus. This is usually done using minimally invasive (laparoscopic) methods, operating through the anus. Therefore, it has increased the demand for the surgery, due to which the market segment is expected to hold the largest market share in the forecast period.

Market Geographical Share

North America region holds the largest market share in the global hirschsprung disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Hirschsprung's disease, well-established infrastructure, novel treatments, increasing awareness about disorders and well-developed diagnosis in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Organization for Rare Disorders, In the United States, 90 percent of initial HSCR diagnoses are made within the first year of life. The majority of the remaining 10% is created throughout early childhood, with less than 1% created during adolescence or adulthood. Constipation is a common complaint among these people, so it's not unexpected that they've had it.

Moreover, according to recent research from the University of Helsinki (UHS), around 1 in every 5000 kids in North America is born lacking enteric neurons in the colon, culminating in hirschsprung disease in maturity. Mutations in the RET receptor on the cell surface cause the condition, which results in colon hypertrophy and constipation in certain cases. Additionally, the Children's Hospital of Los Angeles (CHLA) recently completed a study that promoted stem cells and genetic engineering to treat newborn newborns with hirschsprung disease. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Market Companies

Major key players in the hirschsprung disease treatment market are Pfizer Inc., Fresenius Kabi USA, LLC, Aurobindo Pharma Limited, Sanofi, Allergan, Inc., Laborate Pharmaceuticals.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its drugs and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

Ampicillin for Injection: Ampicillin injection is used to treat certain infections that are caused by bacteria such as meningitis (infection of the membranes that surround the brain and spinal cord) and lung, blood, heart, urinary tract, and gastrointestinal tract infections.